Log in

TSE:MDNAMedicenna Therapeutics Stock Price, Forecast & News

C$5.47
-0.02 (-0.36 %)
(As of 08/7/2020 04:00 PM ET)
Add
Compare
Today's Range
C$5.35
Now: C$5.47
C$5.55
50-Day Range
C$4.87
MA: C$5.31
C$6.02
52-Week Range
C$0.94
Now: C$5.47
C$7.25
Volume46,360 shs
Average Volume120,357 shs
Market CapitalizationC$266.93 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Medicenna Therapeutics Corp., a clinical stage immunotherapy company, develops and commercializes Empowered Cytokines (EC) and Superkines for the treatment of cancer. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that is in the Phase 2b clinical trial for the treatment of recurrent glioblastoma, as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA57 for solid tumors and on-malignant cells of the tumor micro-environment; MDNA109, an IL-2 agonist to treat cancer immunotherapies; MDNA209, an IL-2 antagonist for autoimmune diseases; MDNA413, a dual IL-4/IL-13 antagonist for the treatment of solid tumors, atopic dermatitis, asthma, and fibrosis; and MDNA132, an IL-13 agonist to treat solid tumors and IL 13Ralpha2 chimeric antigen receptor T cell. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 1.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.78 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+1-403-6807898

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Cash FlowC$0.83 per share
Book ValueC$0.77 per share

Profitability

Miscellaneous

EmployeesN/A
Market CapC$266.93 million
Next Earnings DateN/A
OptionableNot Optionable
C$5.47
-0.02 (-0.36 %)
(As of 08/7/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MDNA News and Ratings via Email

Sign-up to receive the latest news and ratings for MDNA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Medicenna Therapeutics (TSE:MDNA) Frequently Asked Questions

How has Medicenna Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Medicenna Therapeutics' stock was trading at C$3.02 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, MDNA stock has increased by 81.1% and is now trading at C$5.47.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Medicenna Therapeutics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medicenna Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Medicenna Therapeutics
.

What price target have analysts set for MDNA?

1 equities research analysts have issued twelve-month price targets for Medicenna Therapeutics' stock. Their forecasts range from C$4.00 to C$4.00. On average, they expect Medicenna Therapeutics' stock price to reach C$4.00 in the next year. This suggests that the stock has a possible downside of 26.9%.
View analysts' price targets for Medicenna Therapeutics
.

Has Medicenna Therapeutics been receiving favorable news coverage?

News articles about MDNA stock have been trending negative recently, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Medicenna Therapeutics earned a news sentiment score of -2.7 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term.
View the latest news about Medicenna Therapeutics
.

Who are some of Medicenna Therapeutics' key competitors?

What other stocks do shareholders of Medicenna Therapeutics own?

Who are Medicenna Therapeutics' key executives?

Medicenna Therapeutics' management team includes the following people:
  • Dr. Fahar Merchant, Founder, Chairman, CEO & Pres (Age 62)
  • Ms. Rosemina Merchant, Founder, Chief Devel. Officer & Director (Age 62)
  • Ms. Elizabeth Williams CPA, CA, CFO & Corp. Sec. (Age 41)
  • Dr. Shafique Fidai Ph.D., Head of Discovery & Corp. Devel.
  • Dr. John Sampson M.D., Ph.D., MBA, Chief Clinical Advisor

What is Medicenna Therapeutics' stock symbol?

Medicenna Therapeutics trades on the Toronto Stock Exchange (TSX) under the ticker symbol "MDNA."

How do I buy shares of Medicenna Therapeutics?

Shares of MDNA and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab.

What is Medicenna Therapeutics' stock price today?

One share of MDNA stock can currently be purchased for approximately C$5.47.

How big of a company is Medicenna Therapeutics?

Medicenna Therapeutics has a market capitalization of C$266.93 million.

What is Medicenna Therapeutics' official website?

The official website for Medicenna Therapeutics is www.medicenna.com.

How can I contact Medicenna Therapeutics?

Medicenna Therapeutics' mailing address is 2440 Kensington Rd NW, CALGARY, AB T2N 3S1, Canada. The company can be reached via phone at +1-403-6807898.

This page was last updated on 8/9/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.